Franklin Biotechnology Discovery Fund Advisor Class (FTDZX)

169.18
Net Asset Value
+0.85%
1 Day
+10.04%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
0.81%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions- the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies- the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

Performance

1 month+5.69% 3 years-3.64%
3 months+8.45% 5 years+12.17%
1 year+12.55% Since inception+17.61%
Data through --

Peer Comparisonvs. Health

 FTDZXCategory
Performance 5-yr return+12.17%+14.50%
Expense ratio0.81%1.29%
Risk 5 year sharpe ratio0.620.94
Net assets$1.4B$3.1B
Average market cap$7.3B$26.3B
Average P/E--25.7
Portfolio turnover27%27%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 20 Years
Minimal initial investment$100,000.00
Minimum IRA investment--

Holdings

U.S. stock91.87%
International stock5.52%
Cash2.33%
Fixed income0.28%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ALXN Alexion Pharmaceuticals Inc7.10%
CELG Celgene5.95%
BIIB Biogen5.02%
VRTX Vertex Pharmaceuticals Inc4.95%
ILMN Illumina Inc4.42%
HRTX Heron Therapeutics Inc3.41%
BMRN Biomarin Pharmaceutical Inc3.14%
REGN Regeneron Pharmaceuticals3.12%
AMGN Amgen3.07%
GILD Gilead Sciences3.04%